





# CT/MRI LI-RADS® v2018 CORE

Untreated observation without pathologic proof in [patient at high risk for HCC](#)



Otherwise, use CT/MRI diagnostic table below



## CT/MRI Diagnostic Table

Arterial phase hyperenhancement (APHE)		No APHE		Nonrim APHE		
Observation size (mm)		< 20	≥ 20	< 10	10-19	≥ 20
Count additional major features:	None	LR-3	LR-3	LR-3	LR-3	LR-4
	One	LR-3	LR-4	LR-4	LR-4 / LR-5	LR-5
	≥ Two	LR-4	LR-4	LR-4	LR-5	LR-5



Observations in this cell are categorized based on one additional major feature:

- LR-4 – if enhancing “capsule”
- LR-5 – if nonperipheral “washout” **OR** threshold growth

*If unsure about the presence of any major feature: characterize that feature as absent*

# Table of Contents

		Pages
Overview	What is LI-RADS®	<a href="#">2</a>
	LI-RADS® Algorithms	<a href="#">3</a>
What's New	What is new in v2018	<a href="#">4</a>
	Why update in 2018	<a href="#">5</a>
Getting Started		<a href="#">6</a>
Categories		<a href="#">7</a>
Diagnosis	Step 1. Apply LI-RADS Diagnostic Algorithm	<a href="#">8</a>
	Step 2. Consider Applying Ancillary Features	<a href="#">9</a>
	Step 3. Apply Tiebreaking Rules if Needed	<a href="#">9</a>
	Step 4. Final Check	<a href="#">10</a>
Treatment Response	Step 1. Apply LI-RADS Treatment Response Algorithm	<a href="#">11</a>
	Step 2. Measure Viable Tumor Size if Applicable	<a href="#">12</a>
	Step 3. Apply Tiebreaking Rule if Needed	<a href="#">12</a>
	Step 4. Final Check	<a href="#">12</a>
Technique	LI-RADS Technical Recommendations	<a href="#">13</a>
Management	Suggested Imaging Workup Options and Time Intervals	<a href="#">14</a>
	OPTN and LI-RADS	<a href="#">15</a>
Reporting	Considerations Before Issuing a LI-RADS Report	<a href="#">16</a>
	Reporting: Requirements and Content	<a href="#">18</a>
Definitions	Imaging Phases	<a href="#">19</a>
	Major Imaging Features	<a href="#">20</a>
	Tumor in Vein	<a href="#">21</a>
	LR-M Criteria	<a href="#">22</a>
	LR-M Reporting	<a href="#">23</a>
	Ancillary Imaging Features Favoring Malignancy	<a href="#">24</a>
	Ancillary Imaging Features Favoring Benignity	<a href="#">25</a>
	LI-RADS Treatment Response Features	<a href="#">26</a>
	Examples of LR-1 and LR-2 Entities	<a href="#">27</a>
Observation with Infiltrative Appearance	<a href="#">28</a>	



# Table of Contents

	Pages
	<a href="#">29</a>
	<a href="#">31</a>
	<a href="#">35</a>
	<a href="#">37</a>
FAQs	<a href="#">38</a>
	<a href="#">45</a>
	<a href="#">48</a>
	<a href="#">50</a>
	<a href="#">52</a>
	<a href="#">55</a>
	<a href="#">58</a>
<hr/>	
CT/MRI Manual (With References) (pending)	

Other LI-RADS Documents (pending): US LI-RADS, CEUS LI-RADS, LI-RADS Downloads



# What is LI-RADS®?

## The Liver Imaging Reporting And Data System (LI-RADS) is:

- A comprehensive system for standardizing the terminology, technique, interpretation, reporting, and data collection of liver imaging
  - A dynamic document, to be expanded and refined as knowledge accrues and in response to user feedback
  - Designed to improve communication, patient care, education, and research
  - Supported and endorsed by the American College of Radiology (ACR)
  - Developed by a multidisciplinary, international consortium of diagnostic and interventional radiologists, hepatobiliary surgeons, hepatologists, and hepatopathologists. Contributors include academic and community physicians as well as members in training.
- 

## LI-RADS may be used for clinical care, education, or research by:

- Community and academic radiologists
  - Radiologists in training
  - Other health care professionals providing care to patients with liver disease
  - Researchers
- 

## LI-RADS is consistent with and fully integrated into:

- AASLD clinical practice guidance
- 

## LI-RADS is consistent with:

- NCCN guidelines
- 

## LI-RADS can be utilized by liver transplant centers in the United States.

- The conversion from LI-RADS categories to OPTN classes is straightforward. See [page 15](#).



# LI-RADS® Algorithms



## Ultrasound LI-RADS®

For **surveillance** of HCC

In **cirrhotic and other high-risk** patients

Using **unenhanced ultrasound**

---



## CEUS LI-RADS®

For **diagnosis** of HCC

In **cirrhotic and other high-risk** patients

Using **contrast-enhanced ultrasound (CEUS)**

---



## CT/MRI Diagnostic LI-RADS®

For **diagnosis and staging** of HCC

In **cirrhotic and other high-risk patients**, including liver transplant candidates with HCC

Using **CT, MRI with extracellular agents (ECA)**, or **MRI with hepatobiliary agents (HBA)**

---



## CT/MRI Treatment Response LI-RADS®

For **assessing response of HCC to locoregional treatment**

In **cirrhotic and other high-risk patients**, including liver transplant candidates with HCC

Using **CT, MRI with extracellular agents (ECA)**, or **MRI with hepatobiliary agents (HBA)**

---

### Notes:

- Multiphase CT or MRI is sometimes used for HCC surveillance, depending on regional guidelines, institutional preferences, and other factors. LI-RADS neither recommends for nor against CT or MRI for this purpose, but LI-RADS may be used to interpret and report those exams if performed.
- LI-RADS v2017 does not address treatment response with CEUS, or after systemic therapy or surgery. These will be addressed in the next LI-RADS version.



# What's New in LI-RADS® v2018?

## Revised, simplified definition of threshold growth

- Threshold growth definition was simplified to:  $\geq 50\%$  size increase of a mass in  $\leq 6$  months.
- **Rationale:** simplicity; achieve concordance with definitions advocated by AASLD and OPTN.
  - AASLD, OPTN, and LI-RADS now have the same definition for threshold growth.



**Note:** the following no longer meet criteria for TG but are considered subthreshold growth:

- New  $\geq 10$  mm observations in  $\leq 24$  months
- $\geq 100\%$  size increase on imaging exams  $> 6$  months apart

## Revised, simplified criteria for LR-5:

- LR-5 criteria were revised to match those advocated by AASLD.
- The -g and -us designations were eliminated for simplicity.
- New LR-5 criteria are listed below and summarized in [Diagnostic Table \(page 8\)](#):

Size	Criteria	Comments
10-19 mm	Nonrim APHE <b>AND</b> <ul style="list-style-type: none"> <li>• Nonperipheral “washout”</li> </ul>	Does not provide exception points for liver transplantation in USA
	Nonrim APHE <b>AND</b> both of the following: <ul style="list-style-type: none"> <li>• Nonperipheral “washout”</li> <li>• Enhancing “capsule”</li> </ul>	Equivalent to OPTN 5A
	Nonrim APHE <b>AND</b> <ul style="list-style-type: none"> <li>• Threshold growth*</li> </ul>	Equivalent to OPTN 5A-g
$\geq 20$ mm	Nonrim APHE <b>AND</b> one or more of following: <ul style="list-style-type: none"> <li>• Nonperipheral “washout”</li> <li>• Enhancing “capsule”</li> <li>• Threshold growth*</li> </ul>	Equivalent to OPTN 5B or 5X

\* Note – apply v2018 definition of threshold growth:  $\geq 50\%$  size increase of a mass in  $\leq 6$  months

- **Rationale:** simplicity; closer concordance with AASLD and OPTN criteria.
  - LI-RADS and AASLD now have identical criteria for definite HCC.
  - LI-RADS and OPTN now have almost identical criteria for HCC, with one exception (below).



**Exception:** 10-19 mm + APHE + nonperipheral “washout” = LR-5, but does not meet OPTN Class 5 criteria

**v2018 also includes clarifications, corrections, new FAQs, and some formatting changes. Most of these are in response to user feedback since v2017 release.**



# Why is an update needed in 2018?

The LI-RADS mission and long-term vision is to unify HCC diagnostic imaging criteria. Recently, a critical milestone was achieved with integration of LI-RADS into the American Association for the Study of Liver Diseases (AASLD) 2018 HCC clinical practice guidance. This integration requires revisions to the definition of the LI-RADS major feature threshold growth and to one LI-RADS category 5 criterion (10-19 mm + arterial phase hyperenhancement + “washout” = LR-5).

Although our intended update cycle is every 3 to 4 years, the recent unification of LI-RADS with AASLD necessitated the expedited release of version 2018 to reflect the above changes.

We hope you appreciate the necessity of this expedited update. We recognize the importance of stability and plan a return to the 3- to 4-year update cycle, with the next major comprehensive update anticipated in 2021.

Thank you for your understanding and for using LI-RADS!

Respectfully,

The LI-RADS Steering Committee

Adrija Mamidipalli  
Alessandro Furlan, Chair, Rad-Path WG  
Alexander Towbin, Chair, Pediatrics WG  
Amit Singal  
Amol Shah  
An Tang, Chair, International WG  
Andrej Lyshchik, Co-Chair, CEUS WG  
Ania Kielar, Co-Chair, Outreach & Education  
Avinash Kambadakone, Chair, Technique WG  
Aya Kamaya, Chair, Ultrasound WG  
Claude Sirlin, Chair, Steering Committee  
Cynthia Santillan  
Demetri Papadatos  
Donald Mitchell  
Elizabeth Hecht, Co-Chair, Management WG  
Eric Ehman  
Evan Siegelman  
Hero Hussain  
Jason Birnbaum  
Jay Heiken, Co-Chair, Hepatobiliary WG

Jeff Weinreb  
Jonathan Hooker  
Judy Wawira  
Kathryn Fowler, Co-Chair, Management WG  
Khaled Elsayes, Co-Chair, Outreach & Education  
Lauren Hicks, ACR Staff  
Marc Kohli, Chair, Tech & Apps WG  
Matt McInnes, Chair, Evidence WG  
Maxime Ronot, Chair, Benign Liver Lesions WG  
Mustafa Bashir, Chair, Gaps in Knowledge WG  
Mythreyi Chatfield, ACR Staff  
Reena Jha  
Richard Do  
Rohit Loomba  
Sasha Roudenko  
Soudabeh Fazeli  
Tom Hope  
Victoria Chernyak, Vice-Chair, Steering Committee  
William Hong  
Yuko Kono, Chair, CEUS WG



# CT/MRI LI-RADS® v2018

## Apply in patients at high risk for HCC, namely those with:



- Cirrhosis **OR**
- Chronic hepatitis B viral infection **OR**
- Current or prior HCC

Including adult liver transplant candidates and recipients posttransplant

## Do not apply in patients:



- Without the above risk factors
- < 18 years old
- With cirrhosis due to congenital hepatic fibrosis
- With cirrhosis due to a vascular disorder such as hereditary hemorrhagic telangiectasia, Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, or diffuse nodular regenerative hyperplasia

## Apply for multiphase exams performed with:



- CT or MRI with extracellular contrast agents (ECA) **OR**
- MRI with hepatobiliary contrast agents (HBA)

## Do not assign LI-RADS categories for observations:



- That are path-proven malignancies **OR**
- That are path-proven benign lesions of non-hepatocellular origin such as hemangiomas

See [page 50](#) for guidance on reporting path-proven lesions.

# CT/MRI LI-RADS® v2018 Categories

## Diagnostic Categories

LR-NC	Not categorizable (due to image omission or degradation)	
LR-1	Definitely benign	
LR-2	Probably benign	
LR-3	Intermediate probability of malignancy	
Probably or definitely malignant, not necessarily HCC	LR-4	Probably HCC
	LR-5	Definitely HCC
LR-TIV	Tumor in vein	


## Treatment Response Categories

LR-TR Nonevaluable	Treated, Response not evaluable (due to image omission or degradation)
LR-TR Nonviable	Treated, Probably or definitely not viable
LR-TR Equivocal	Treated, Equivocally viable
LR-TR Viable	Treated, Probably or definitely viable




# Step 1. Apply CT/MRI LI-RADS® Diagnostic Algorithm

Untreated observation without pathologic proof in [patient at high risk for HCC](#)



Otherwise, use CT/MRI diagnostic table below



## CT/MRI Diagnostic Table

Arterial phase hyperenhancement (APHE)		No APHE		Nonrim APHE		
		< 20	≥ 20	< 10	10-19	≥ 20
Observation size (mm)						
Count additional major features: • Enhancing “capsule” • Nonperipheral “washout” • Threshold growth	None	LR-3	LR-3	LR-3	LR-3	LR-4
	One	LR-3	LR-4	LR-4	LR-4 / LR-5	LR-5
	≥ Two	LR-4	LR-4	LR-4	LR-5	LR-5



Observations in this cell are categorized based on one additional major feature:

- LR-4 – if enhancing “capsule”
- LR-5 – if nonperipheral “washout” **OR** threshold growth

*If unsure about the presence of any major feature: characterize that feature as absent*

OPTN users in USA: see [page 15](#) for conversion of LI-RADS® categories to OPTN Classes




# Step 2. Optional: Apply Ancillary Features (AFs)

Ancillary features may be used **at radiologist discretion** for:  
Improved detection, increased confidence, or category adjustment

For **category adjustment** (upgrade or downgrade), apply ancillary features as follows:

≥ 1 AF favoring malignancy: upgrade by 1 category up to LR-4  
(Absence of these AFs should not be used to downgrade)



≥ 1 AF favoring benignity: downgrade by 1 category  
(Absence of these AFs should not be used to upgrade)

If ≥ 1 AF favoring malignancy and ≥ 1 AF favoring benignity:  
Do not adjust category

*Ancillary features cannot be used to upgrade to LR-5*

## Ancillary features favoring malignancy

### Favoring malignancy in general, not HCC in particular

- US visibility as discrete nodule
- Subthreshold growth
- Restricted diffusion
- Mild-moderate T2 hyperintensity
- Corona enhancement
- Fat sparing in solid mass
- Iron sparing in solid mass
- Transitional phase hypointensity
- Hepatobiliary phase hypointensity

### Favoring HCC in particular

- Nonenhancing “capsule”
- Nodule-in-nodule
- Mosaic architecture
- Blood products in mass
- Fat in mass, more than adjacent liver

## Ancillary features favoring benignity


- Size stability > 2 yrs
- Size reduction
- Parallels blood pool
- Undistorted vessels
- Iron in mass, more than liver
- Marked T2 hyperintensity
- Hepatobiliary phase isointensity

*If unsure about presence of any ancillary feature: characterize that feature as absent*




## Step 3. Apply Tiebreaking Rules if Needed

If unsure about presence of TIV, do not categorize as LR-TIV



If unsure between two categories, choose the one reflecting lower certainty



## Step 4. Final Check

After Steps 1, 2, and 3 –


Ask yourself if the assigned category seems reasonable and appropriate

**If YES:** You are done, move on the next observation (if any).

**If NO:** Assigned LI-RADS category may be inappropriate, so reevaluate.



# Step 1. Apply LI-RADS® CT/MRI Treatment Response Algorithm





## CT/MRI Treatment Response Table

Response Category	Criteria
<b>LR-TR Nonviable</b>	<ul style="list-style-type: none"> <li>No lesional enhancement <b>OR</b></li> <li>Treatment-specific expected enhancement pattern</li> </ul>
<b>LR-TR Equivocal</b>	Enhancement atypical for treatment-specific expected enhancement pattern and not meeting criteria for probably or definitely viable
<b>LR-TR Viable</b>	Nodular, masslike, or thick irregular tissue in or along the treated lesion with any of the following: <ul style="list-style-type: none"> <li>Arterial phase hyperenhancement <b>OR</b></li> <li>Washout appearance <b>OR</b></li> <li>Enhancement similar to pretreatment</li> </ul>



## Step 2. Measure Viable Tumor Size



**Size of equivocally, probably, or definitely viable tumor**

Longest dimension through enhancing area of treated lesion, not traversing nonenhancing area

## Step 3. Apply Tiebreaking Rule if Needed

If unsure between two categories, choose the one reflecting lower certainty as illustrated below



## Step 4. Final Check

After Steps 1, 2, and 3 -

Ask yourself if the assigned response category seems reasonable and appropriate

**If YES:** You are done, move on the next observation (if any).

**If NO:** Assigned LI-RADS category may be inappropriate, so reevaluate.



# CT/MRI LI-RADS® v2018

## Technical Recommendations

### CT

Recommended equipment	<ul style="list-style-type: none"> <li>Multidetector CT with <math>\geq 8</math> detector rows</li> </ul>
Required images	<ul style="list-style-type: none"> <li>Arterial phase (late arterial phase strongly preferred)</li> <li>Portal venous phase</li> <li>Delayed phase</li> </ul>
Suggested images	<ul style="list-style-type: none"> <li>Precontrast, if patient has had locoregional treatment</li> <li>Multiplanar reformations</li> </ul>

### MRI with extracellular contrast agents or gadobenate dimeglumine

Recommended equipment	<ul style="list-style-type: none"> <li>1.5T or 3T</li> <li>Torso phased-array coil</li> </ul>
Required images	<ul style="list-style-type: none"> <li>Unenhanced T1-weighted OP and IP imaging</li> <li>T2-weighted imaging (fat suppression per institutional preference)</li> <li>Multiphase T1-weighted imaging             <ul style="list-style-type: none"> <li>Precontrast imaging</li> <li>Arterial phase (late arterial phase strongly preferred)</li> <li>Portal venous phase</li> <li>Delayed phase</li> </ul> </li> </ul>
Suggested or optional images	<ul style="list-style-type: none"> <li>Diffusion-weighted imaging</li> <li>Subtraction imaging</li> <li>Multiplanar acquisition</li> <li>1- to 3-hr hepatobiliary phase with gadobenate dimeglumine (same sequence type as for multiphase, may use higher flip angle to increase T1 contrast)</li> </ul>

### MRI with gadoxetate disodium


Recommended equipment	<ul style="list-style-type: none"> <li>1.5T or 3T</li> <li>Torso phased-array coil</li> </ul>
Required images	<ul style="list-style-type: none"> <li>Unenhanced T1-weighted OP and IP imaging</li> <li>T2-weighted imaging (fat suppression per institutional preference)</li> <li>Multiphase T1-weighted imaging             <ul style="list-style-type: none"> <li>Precontrast imaging</li> <li>Arterial phase (late arterial phase strongly preferred)</li> <li>Portal venous phase</li> <li>Transitional phase (2 to 5 minutes after injection)</li> <li>Hepatobiliary phase (same sequence type as for earlier phases, may use higher flip angle to increase T1 contrast)</li> </ul> </li> </ul>
Suggested or optional images	<ul style="list-style-type: none"> <li>Diffusion-weighted imaging</li> <li>Subtraction imaging</li> <li>Multiplanar acquisitions</li> </ul>




# CT/MRI LI-RADS®-Based Management: Suggested Imaging Workup Options & Time Intervals

Below are management suggestions by AASLD and LI-RADS in consensus.

## Untreated observations



## Treated observations





# OPTN and LI-RADS® (for LI-RADS Users in USA)

- OPTN system assigns HCC exception points for liver transplant candidates with HCC in USA
- CT/MRI LI-RADS can be applied to liver transplant candidates meeting LI-RADS eligibility criteria (See [page 6](#)).
- Basic information regarding LI-RADS and OPTN is provided below:

**Imaging technique**    **OPTN technical requirements are nearly identical to LI-RADS, except LI-RADS provides guidance for use of gadoxetate disodium.**

**Reporting**    **Observations contributing to OPTN staging (i.e., LR-5, LR-5g, path-proven HCC) should be reported with the following information:**

- Size or size of the viable tumor if treated
- Major features used for categorizing

**Although they do not meet OPTN 5A or 5B criteria:**

- LR-M and LR-TIV should be reported, as they may affect pretransplant workup and/or transplant eligibility
- LR-4 and 10-19 mm LR-5 observations with nonrim APHE and nonperipheral “washout” but without enhancing “capsule” or threshold growth should be reported, as there is high likelihood they represent HCC, and their presence may suggest multifocal HCC

**Caveats**    **OPTN and LI-RADS criteria for definite HCC are identical except for:**

10-19 mm observations with nonrim APHE + nonperipheral “washout” but without enhancing “capsule” or threshold growth:

- OPTN: these are not assigned any OPTN Class.
- LI-RADS: these are categorized LR-5 (consistent with AASLD).

Implication: Some LR-5 observations do not count as OPTN 5.

**OPTN and LI-RADS populations differ:**

- OPTN: applies to all transplant candidates
- LI-RADS: applies only to transplant candidates meeting eligibility criteria ([page 6](#))

Implication: OPTN may be applied in some transplant candidates for whom LI-RADS is not recommended due to incomplete validation of imaging for noninvasive diagnosis of HCC. This includes pediatric patients and vascular causes of cirrhosis.



# CT/MRI LI-RADS® v2018 Reporting: Considerations Before Issuing a LI-RADS® Report

## Use your judgment and common sense

If a patient has multiple observations:

- Decide whether to report observations individually, in aggregate, or as a combination of both, with the goal of communicating your findings and impression most clearly.

Tailor your recommendations to your patient.

- [Page 14](#) provides general guidance for imaging workup options, but optimal management may vary depending on the observation or patient.

---

## Is any observation path-proven to your knowledge?

If an observation has been biopsied and there is no uncertainty about the path diagnosis (i.e., the path diagnosis is a malignant entity such as HCC or the path diagnosis is a non-hepatocellular benign entity such as hemangioma), report the path diagnosis rather than the LI-RADS category.

If an observation has been biopsied but there is either uncertainty about the path diagnosis or the path diagnosis is a potential HCC precursor (i.e. regenerative or dysplastic nodule), report the LI-RADS category and the path diagnosis together. See [page 31](#) for further guidance and rationale.

---

## Is there tumor in vein?

If yes, report the likely etiology. Most LR-TIV observations are HCC but some may be iCCA, cHCC-CCA, or other non-HCC malignancies. See [page 21](#) for further guidance.

---

## Is there a LR-M observation?

If yes, report the likely etiology if possible. The differential diagnosis of LR-M includes iCCA, cHCC-CCA, other non-HCC malignancies, as well as HCC with atypical imaging features. See [page 23](#) for further guidance.

---

## Avoid language that compels biopsy or other invasive procedure

If consideration for liver biopsy is appropriate, the following phrases might be used:

- “Options for diagnostic workup include \_\_\_\_ and possibly biopsy.”
- “If distinction between HCC and \_\_\_\_ would be helpful, biopsy may be considered.”
- “Biopsy may be necessary to distinguish between HCC and \_\_\_\_.”
- “...probably HCC. To establish a definite diagnosis, biopsy may be considered.”



# CT/MRI LI-RADS® v2018 Reporting: Considerations Before Issuing a LI-RADS® Report

## Is your patient a liver transplant candidate in the USA?

If yes, the LI-RADS category needs to be converted to OPTN Class by the radiologist or transplant team. The conversion is straightforward if the following are reported: size, major features, and number of LR-5\* observations and of path-proven HCCs – or the viable tumor size if treated. For more advanced disease, report the presence of nodal or distant metastasis and LR-TIV observations. Also, report LR-M observations as these may affect transplant eligibility.

\* Remember that although categorized LR-5, 10-19 mm observations with nonrim APHE and nonperipheral "washout" as the only additional major feature are not considered OPTN Class 5A for HCC exception points in the USA



# CT/MRI LI-RADS® v2018 Reporting:

Untreated observation	Reporting requirement	Recommended report content
No observation	Should be reported in Impression.	“There are no reportable LI-RADS observations.”
LR-NC	Must be reported in Impression.	Provide causative technical limitations or artifacts, and work-up suggestions.
LR-1 LR-2	Summarize in aggregate <b>OR</b> Report in Impression if: was suspicious nodule on the antecedent ultrasound or was LR-4, -5, or -M on prior.	Provide category range and approximate number of observations. If downgrading from prior exam, provide rationale.
LR-3	Report in Impression if: no higher category observations or was LR-4, LR-5, or LR-M on prior.	Provide major features, growth, and contributory ancillary features. Indicate relevant change since prior.
LR-4 LR-5 LR-M	Must be reported in Findings and Impression. May summarize in aggregate for clarity.	Provide major features, growth, contributory ancillary & other features. Indicate relevant change since prior. For LR-M: indicate likely etiology if possible (see <a href="#">page 23</a> )
LR-TIV	Must be reported in Findings and Impression.	Indicate likely etiology (see <a href="#">page 21</a> ); describe vessel(s) involved and categorize parenchymal mass if any
Treated observation	Reporting requirement	Recommended report content
LR-TR Nonevaluable	Must be reported in Findings and Impression.	Provide causative technical limitations or artifacts, and work-up suggestions.
LR-TR Nonviable LR-TR Equivocal LR-TR Viable	Must be reported in Findings and Impression. May summarize in aggregate for clarity.	Provide pretreatment category and size, current response category. For TR viable or equivocal: Report viable tumor size (or range if in aggregate), criteria for viability, and change since prior.

### All reported observations should include

- **Identifier:** sequential number or other unique identifier, kept fixed on all exams.
- **Series & image number where size is measured.** If possible, also save key images on PACS.



# LI-RADS® CT/MRI Phases

## Arterial phase (AP)

Early AP

Late AP



In LI-RADS, the arterial phase refers to the hepatic arterial phase unless otherwise specified. The arterial phase is a postcontrast injection time range with the following characteristics:

- Hepatic artery and branches are fully enhanced.
- Hepatic veins not yet enhanced by antegrade flow.

Two subtypes:

- Early AP: Subtype of AP in which portal vein is not yet enhanced.
- Late AP: Subtype of AP in which portal vein is enhanced.

*Late AP* is strongly preferred for HCC diagnosis and staging, because the degree of enhancement in HCC usually is higher in the late than in the early AP. Some HCCs may show hyperenhancement only in the late AP.

## Extracellular phase (ECP)

Postcontrast phase in which liver enhancement is attributable mainly to extracellular distribution of a contrast agent. Operationally, this refers to:

- PVP and DP if an extracellular agent or gadobenate is given.
- PVP only if gadoxetate is given.

## Portal venous phase (PVP)



Postcontrast injection time range with the following characteristics:

- Portal veins are fully enhanced.
- Hepatic veins are enhanced by antegrade flow.
- Liver parenchyma usually is at peak enhancement.

## Delayed phase (DP)



Postcontrast phase acquired with extracellular agents or gadobenate after the portal venous phase and with the following characteristics:

- Portal and hepatic veins are enhanced but less than in PVP.
- Liver parenchyma is enhanced but usually less than in PVP.

Typically acquired 2 to 5 minutes after injection.

## Transitional phase (TP)



Postcontrast phase acquired with a hepatobiliary agent after the extracellular phase, before the hepatobiliary phase, and with the following characteristics:

- Liver vessels and hepatic parenchyma are of similar signal intensity.
- Both the intracellular and extracellular pools of the agent contribute substantially to parenchymal enhancement.

Typically acquired 2 to 5 minutes after injection of gadoxetate.  
Typically not obtained with gadobenate.

## Hepatobiliary phase (HBP)



Postcontrast phase acquired with a hepatobiliary agent where:

- Liver parenchyma is hyperintense to hepatic blood vessels.
- There is excretion of contrast into biliary system.

Typically acquired about 20 minutes after injection with gadoxetate.  
Typically not obtained with gadobenate. If obtained, typically acquired 1-3 hours after injection with gadobenate.

HBP is suboptimal if liver is not more intense than hepatic blood vessels.



# LI-RADS® Major Imaging Features

## Nonrim APHE



Nonrim-like enhancement in arterial phase unequivocally greater in whole or in part than liver. Enhancing part must be higher in attenuation or intensity than liver in arterial phase. *Contrast with [rim APHE](#) (inclusion criterion for LR-M, [page 22](#)).*

## Nonperipheral “washout”



Nonperipheral visually assessed temporal reduction in enhancement in whole or in part relative to composite liver tissue from earlier to later phase resulting in hypoenhancement in the extracellular phase:

- portal venous or delayed phase if ECA or gadobenate is given
- portal venous phase if gadoxetate is given

Can apply to any enhancing observation, even if no APHE. *Contrast with [peripheral “washout”](#) (inclusion criterion for LR-M, [page 22](#)) or TP or HBP hypointensity (ancillary features favoring malignancy, [page 24](#)).*

## Enhancing “capsule”



Smooth, uniform, sharp border around most or all of an observation, unequivocally thicker or more conspicuous than fibrotic tissue around background nodules, and visible as an enhancing rim in PVP, DP, or TP. *Contrast with [nonenhancing capsule](#) (ancillary feature favoring HCC, [page 24](#)) or [corona enhancement](#) (ancillary feature favoring malignancy, [page 24](#)).*


## Size



Largest outer-edge-to-outer-edge dimension of an observation:

- Include “capsule” in measurement.
- Pick phase, sequence, plane in which margins are clearest.
- Do not measure in arterial phase or DWI if margins are clearly visible on different phase (size may be overestimated in arterial phase due to summation with perioobservation enhancement and is not measured reliably on DWI due to anatomic distortion).

## Threshold growth



Size increase of a mass by  $\geq 50\%$  in  $\leq 6$  months

- Apply threshold growth *only* if the observation unequivocally is a mass. Do not apply threshold growth if there is a reasonable possibility that the observation is a pseudolesion such as a perfusion alteration. See [page 57](#) for discussion on how to differentiate masses from pseudolesions.
- Apply threshold growth *only* if there is a prior CT or MRI exam of sufficient quality and appropriate technique to gauge if growth has occurred. Do not assess threshold growth by comparing to prior US or CEUS exams.
- Measure on same phase, sequence, and plane on serial exams if possible.



# LI-RADS® Tumor in Vein

## Tumor in vein

**LR-TIV**

Unequivocal enhancing soft tissue in vein, regardless of visualization of parenchymal mass

### Additional clues to diagnosis of tumor in vein:

Imaging features that suggest tumor in vein but do NOT establish its presence are listed below:

- Occluded vein with ill-defined walls
- Occluded vein with restricted diffusion
- Occluded or obscured vein in contiguity with malignant parenchymal mass
- Heterogeneous vein enhancement not attributable to artifact

If these features are seen, scrutinize vein for enhancing soft tissue.

### Categorization:


Categorize as LR-TIV.

### Reporting:

Indicate in report most probable etiology.

See below for guidance:

**LR-TIV**





# LR-M Criteria

Targetoid mass (see below for definition and imaging appearances)

**OR**

Nontargetoid mass with one or more of the following:

- Infiltrative appearance. See [page 28](#).
- Marked diffusion restriction. See manual (pending).
- Necrosis or severe ischemia. See manual (pending).
- Other feature that in radiologist’s judgment suggests non-HCC malignancy (specify in report). See manual (pending).

No tumor in vein  
Not meeting LR-5 criteria

## Targetoid, definition

Target-like imaging morphology. Concentric arrangement of internal components. Likely reflects peripheral hypercellularity and central stromal fibrosis or ischemia.

Characteristic of

- Intrahepatic cholangiocarcinoma (iCCA)
- Combined HCC-cholangiocarcinoma (combined HCC-CCA or cHCC-CCA)
- Other non-HCC malignancies

Can be seen in HCC with atypical appearance.

Therefore, targetoid appearance suggests non-HCC malignancy but does not exclude HCC.

## Targetoid mass, imaging appearance on various phases or sequences

Targetoid dynamic enhancement:

	Rim APHE	Spatially defined subtype of APHE in which arterial phase enhancement is most pronounced in observation periphery
	Peripheral “washout”	Spatially defined subtype of “washout” in which apparent washout is most pronounced in observation periphery
	Delayed central enhancement	Central area of progressive postarterial phase enhancement

Targetoid appearance on DWI or TP/HBP:

	Targetoid restriction	Concentric pattern on DWI characterized by restricted diffusion in observation periphery with less restricted diffusion in observation center
	Targetoid TP or HBP appearance	Concentric pattern in TP or HBP characterized by moderate-to-marked hypointensity in observation periphery with milder hypointensity in center



# LR-M Criteria


## Reporting:

The differential diagnosis of LR-M includes

- More common: HCC with atypical imaging features, iCCA, cHCC-CCA
- Less common: other primary or metastatic malignancies, benign entities such as sclerosing hemangiomas and abscesses

If possible, radiologists should indicate in their report the most probable etiology for each LR-M observation, as this information may influence management, including the need and urgency for biopsy.

The algorithm below provides imaging-based guidance for determining and reporting the most probable etiology among the more common causes. Elevations in circulating tumor biomarkers such as AFP and CA 19-9, if available, can also refine the differential diagnosis (see [FAQs page 39](#)).



Algorithm above is not exhaustive. It addresses only the more common diagnostic considerations encountered in at-risk patients.



# LI-RADS® Ancillary Imaging Features Favoring Malignancy & The Imaging Modalities in Which They Are Visible

## Ancillary features favoring malignancy, not HCC in particular

Feature	Definition	CT	MRI ECA	MRI HBA
US visibility as discrete nodule	Unenhanced US visibility as discrete nodule or mass corresponding to CT- or MRI-detected observation	+	+	+
Subthreshold growth	Unequivocal size increase of a mass, less than threshold growth. See <a href="#">page 20</a> for definition of threshold growth.	+	+	+
Corona enhancement	Periobservational enhancement in late arterial phase or early PVP attributable to venous drainage from tumor	+	+	+
Fat sparing in solid mass	Relative paucity of fat in solid mass relative to steatotic liver <b>OR</b> in inner nodule relative to steatotic outer nodule	+ / -	+	+
Restricted diffusion	Intensity on DWI, not attributable solely to T2 shine-through, unequivocally higher than liver and/or ADC unequivocally lower than liver	—	+	+
Mild-moderate T2 hyperintensity	Intensity on T2WI mildly or moderately higher than liver and similar to or less than non-iron-overloaded spleen	—	+	+
Iron sparing in solid mass	Paucity of iron in solid mass relative to iron-overloaded liver <b>OR</b> in inner nodule relative to siderotic outer nodule	—	+	+
Transitional phase hypointensity	Intensity in the transitional phase unequivocally less, in whole or in part, than liver	—	—	+
Hepatobiliary phase hypointensity	Intensity in the hepatobiliary phase unequivocally less, in whole or in part, than liver	—	—	+

## Ancillary features favoring HCC in particular

Feature	Definition	CT	MRI ECA	MRI HBA
Nonenhancing “capsule”	Capsule appearance not visible as an enhancing rim. See <a href="#">page 20</a> for definition of enhancing “capsule”.	+	+	+
Nodule-in-nodule architecture	Presence of smaller inner nodule within and having different imaging features than larger outer nodule	+	+	+
Mosaic architecture	Presence of randomly distributed internal nodules or compartments, usually with different imaging features	+	+	+
Fat in mass, more than adjacent liver	Excess fat within a mass, in whole or in part, relative to adjacent liver	+ / -	+	+
Blood products in mass	Intralesional or perilesional hemorrhage in the absence of biopsy, trauma or intervention	+ / -	+	+

+ usually evaluable    — not evaluable    + / - may or may not be evaluable

ADC = apparent diffusion coefficient, DWI = diffusion-weighted imaging, ECA = extracellular agent, HBA = hepatobiliary agent, PVP = portal venous phase, T2WI = T2-weighted imaging



# LI-RADS® Ancillary Imaging Features Favoring Benignity & The Imaging Modalities in Which They Are Visible

## Ancillary features favoring benignity

Feature	Definition	CT	MRI ECA	MRI HBA
Size stability ≥ 2 years	No significant change in observation size measured on exams ≥ 2 years apart in absence of treatment	+	+	+
Size reduction	Unequivocal spontaneous decrease in size over time, not attributable to artifact, measurement error, technique differences, or resorption of blood products	+	+	+
Parallels blood pool enhancement	Temporal pattern in which enhancement eventually reaches and then matches that of blood pool	+	+	+
Undistorted vessels	Vessels traversing an observation without displacement, deformation, or other alteration	+	+	+
Iron in mass, more than liver	Excess iron in a mass relative to background liver	+ / -	+	+
Marked T2 hyperintensity	Intensity on T2WI markedly higher than liver and similar to bile ducts and other fluid-filled structures	—	+	+
Hepatobiliary phase isointensity	Intensity in hepatobiliary phase nearly identical to liver	—	—	+

+ usually evaluable    – not evaluable    + / – may or may not be evaluable

ECA = extracellular agent, HBA = hepatobiliary agent, T2WI = T2-weighted imaging



# LI-RADS® Treatment Response Features

## Viability

Presence of live tumor cells within or along the margin of a treated lesion.

Radiologic viability is not synonymous with pathologic viability as imaging is not sensitive to microscopic or small foci of residual tumor.

## Treatment-specific expected enhancement



Expected temporal and spatial pattern of posttreatment enhancement attributable to treatment-related changes in parenchymal perfusion.

For some treatments, early posttreatment enhancement patterns may not reliably differentiate viable from nonviable tumor. In the early postprocedural period for such treatments, the most appropriate response category may be LR-TR Equivocal.

## No lesional enhancement



Absence of enhancement within or along the margin of a treated lesion.

Note: complete disappearance after locoregional treatment is considered equivalent to absence of enhancement.

## Posttreatment APHE



Nodular, masslike, or thick and irregular APHE contained within or along the margin of a treated lesion suggests posttreatment tumor viability.

## Posttreatment "washout"



Nodular, masslike, or thick and irregular washout appearance contained within or along the margin of a treated lesion suggests posttreatment tumor viability.

## Posttreatment enhancement similar to pretreatment



Nodular, masslike, or thick and irregular enhancement similar to pretreatment enhancement in all postcontrast phases contained within or along the margin of a treated lesion suggests posttreatment tumor viability, even in the absence of APHE or washout appearance.



# Examples of LR-1 and LR-2 Entities

LR-1

Definite:

- Cyst
- Hemangioma
- Perfusion alteration (e.g., arteriportal shunt)
- Hepatic fat deposition/sparing
- Hypertrophic pseudomass
- Confluent fibrosis or focal scar

Spontaneous disappearance

*List above not meant to be exhaustive*

LR-2

Probable:

- Cyst
- Hemangioma
- Perfusion alteration (e.g., arteriportal shunt)
- Hepatic fat deposition/sparing
- Hypertrophic pseudomass
- Confluent fibrosis or focal scar

Distinctive nodule without malignant imaging features (see below)

*List above not meant to be exhaustive*

Solid nodule < 20 mm distinctive in imaging appearance compared to background nodules **AND** with no major feature of HCC, no feature of LR-M, and no ancillary feature of malignancy.

Distinctive nodule without malignant features

Common examples:

- T1 hyperintense
- T2 hypointense
- Siderotic
- HBP hyperintense
- Any combination of above

No APHE, WO, capsule, or growth  
No feature of LR-M (see [page 22](#))  
No ancillary feature of malignancy (see [page 24](#))

*If ≥ 20 mm, categorize as LR-3 or higher depending on imaging features*



**Caution:** Nodules with features suggestive of focal nodular hyperplasia (FNH) or hepatocellular adenoma (HCA) usually should be categorized LR-3. With caution, they may be categorized LR-2. They should not be categorized LR-1.

Rationale: these are diagnoses of exclusion in high-risk patients.



# Observation with Infiltrative Appearance



Observation with infiltrative appearance

Observation with non-circumscribed margin (indistinct transition) thought to represent malignancy with permeative growth pattern.

## Terminology:

- Malignancies with permeative growth pattern are frequently termed “infiltrative”.
- LI-RADS prefers the term infiltrative appearance. Rationale: may represent true infiltration of tumor cells into liver parenchyma, confluence of tiny nodules, or both. The distinction is difficult.

## Differential diagnosis for malignancies with infiltrative CT and MRI appearance:

- Common: HCC
- Uncommon: iCCA, cHCC-CCA, metastasis to liver from extrahepatic primary, lymphoma


## CT and MRI detection of malignancies with infiltrative appearance:

- May manifest as diffuse ill-defined mass, often involving more than one segment
- Despite large size, may be difficult to detect
  - Pre-contrast imaging may help.
  - Careful analysis of all available images frequently is necessary.
- Suggestive features (partial list):
  - Tumor in vein (often first and most helpful clue)
  - Obscured or non-visualized veins not attributable to chronic benign occlusion
  - Heterogeneous attenuation/signal intensity
  - Mild-to-moderate T1 hypointensity, T2 hyperintensity, restricted diffusion
  - Heterogeneous enhancement in one or more phases
  - Presence of multiple vague or ill-defined nodules
  - Architectural distortion

**Pitfall:** Some benign processes may have infiltrative appearances and be misinterpreted as malignant. Examples: focal or regional alteration in perfusion, fat deposition, iron deposition. Clue: these do not invade veins, obscure vessels, or distort parenchymal architecture.

## LI-RADS categorization of ill-defined observations:

Ill-defined observation without pathologic proof in patient at high risk for HCC





# Getting Started

## What is a LI-RADS observation?

An observation is a distinctive area compared to background liver at imaging. It may be a lesion (mass or nodule) or pseudolesion (e.g., perfusion alteration, hypertrophic pseudomass, or artifact).

---

## The term “observation” is clunky. Can I use another term?

“Observation” generically applies to any apparent abnormality detected at imaging. As a generic term, it is preferred over “lesion” or “nodule”, since some observations (e.g. perfusion alterations, artifacts) may represent pseudolesions rather than true lesions or nodules. For these reasons, the LI-RADS decision tree and algorithm use the generic term “observation”. In clinical, educational, and research settings, however, use of narrower terms may provide clearer and more succinct communication. Depending on the context, it is acceptable to use the narrowest term for which there is certainty. For example, if there is certainty that a given observation is a true lesion rather than a pseudolesion, then the term “lesion” is acceptable. If there is certainty that the given observation is a nodule, then the narrower term “nodule” is acceptable. For more information, see Manual (pending).

---

## Why does LI-RADS not apply to patients without risk factors, to patients < 18 years old, or to patients with cirrhosis due to congenital hepatic fibrosis?

The positive predictive value of imaging for HCC may not be sufficiently high in such patients.

---

## Why does LI-RADS not apply to patients with cirrhosis due to a vascular disorder such as hereditary hemorrhagic telangiectasia, Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, or diffuse nodular regenerative hyperplasia?

Such conditions are associated with formation of benign hyperplastic nodules that may resemble HCC on imaging, potentially causing false positive diagnoses.

---

## I am not sure if my patient has cirrhosis. Can I apply CT/MRI LI-RADS?

You can apply LI-RADS and provide a conditional category. For example: “25 mm mass with APHE and washout appearance. If the patient has cirrhosis or chronic hepatitis B, this meets criteria for LR-5 (definitely HCC).”

---

## My institution is a transplant center and is required to use the OPTN system. Can I use LI-RADS instead of or in addition to OPTN?

Yes, you may use LI-RADS in any patient with cirrhosis, chronic hepatitis B, or current or prior HCC. This includes liver transplant candidates and/or recipients with any of those risk factors.



# Getting Started

## **My patient has active extrahepatic primary malignancy. Can I use LI-RADS?**

Yes. LI-RADS may be applied, but assignment of LR-5 should be done with caution because LI-RADS imaging criteria and observation categories were not developed or validated in this setting. Concurrent extrahepatic malignancy reduces the positive predictive value of LR-5 for HCC, especially if the primary tumor is hypervascular. If in doubt, categorize as LR-M rather than LR-5; consider additional imaging and multidisciplinary discussion.

---

## **Can I use the LI-RADS diagnostic algorithm in a patient who has cirrhosis and heart failure?**

Yes. LI-RADS can be used in a patient with cirrhosis and heart failure, as long as the cirrhosis is not due to the heart failure or other vascular disorder (see [page 4](#)).

---

## **Why does LI-RADS not apply to single-phase CT or MRI exams?**

Characterization of all LI-RADS major imaging features is possible only if multiple imaging phases are acquired. See [page 13](#) for LI-RADS technical recommendations.

---

## **How do I interpret and report observations on single-phase CT or MRI in at-risk patients?**

Provide your best diagnosis or differential diagnosis. Suggest multiphase CT or MRI if a formal LI-RADS categorization would help in patient management.

---

## **Why shouldn't I assign a LI-RADS category for path-proven malignancies and for path-proven benign lesions of non-hepatocellular origin?**

LI-RADS is intended to clarify communication. Assigning a LI-RADS category to a pathologically proven lesion (in which there is now certainty about the diagnosis) may cause confusion, especially for LI-RADS categories that convey some uncertainty (i.e., LR-2, LR-3, LR-4, or LR-M).

---

## **Should I assign a LI-RADS category to path-proven benign lesions of hepatocellular origin (e.g., regenerative or dysplastic nodules)?**

These are exceptions to the prior rule. For path-proven regenerative or dysplastic nodules, assign a LI-RADS category in addition to the path diagnosis. Assigning LI-RADS categories alleviates potential harm from false-negative pathology, facilitates monitoring of nodules for possible progression, and informs management decisions.

---



## What's New

### **Why did LI-RADS change the LR-5 criteria?**

To achieve congruency with the new AASLD criteria released in 2018.

---

### **How will this affect the specificity of LR-5 for diagnosis of HCC?**

The revised criteria are slightly less stringent; some specificity reduction is expected. The reduction is likely to be small, however, as prior studies have shown that in high-risk patients, the combination of 10-19 mm size, nonrim APHE, and nonperipheral “washout” provides > 90% specificity for HCC.

---

### **Why did LI-RADS eliminate the –us and –g designations?**

For simplicity and based on feedback from international users that the designations are irrelevant outside the United States and introduce unnecessary complexity.

---

### **Why did LI-RADS v2018 change the definition of threshold growth?**


For simplicity and concordance with AASLD and OPTN criteria.



# What's New


## How does the change in definition impact the characterization of growth?

The impact on categorization is summarized below:



## How do the changes introduced in v2018 impact categorization?


The impact on categorization is summarized below:



# What's New

## How do the changes introduced in v2018 impact categorization? (Cont'd)


The impact on categorization is summarized below:



# What's New

I am a radiologist at a transplant center in the USA. What are the key differences between LI-RADS 5 and OPTN Class 5?

There is only one substantive difference between LI-RADS 5 and OPTN Class 5:



## What are other differences?

Other differences relate to nomenclature. For example:

Features	LI-RADS v2018	OPTN
10-19 mm + APHE + TG	LR-5	OPTN 5A-g
10-19 mm + APHE + nonperipheral "washout" + enhancing "capsule"	LR-5	OPTN 5A
20-50 mm + APHE + 1 or more additional major features	LR-5	OPTN 5B
> 50 mm + APHE + 1 or more additional major features	LR-5	OPTN 5X
Enhancing soft tissue in vein	LR-TIV	OPTN 5X
One or more features of LR-M	LR-M	Does not meet criteria for HCC

# LI-RADS® Diagnostic Categories

## What are LI-RADS diagnostic categories?

They are categories reflecting the probability of HCC, non-HCC malignancy or benignity.


## Do LI-RADS diagnostic categories correspond exactly to histological categories?

No, the categories reflect probabilities; they do not correspond to exact histological categories.

For example, while all LR-1 observations are benign, not all benign entities can be categorized LR-1. In particular, regenerative nodules and low-grade dysplastic nodules cannot be categorized LR-1 because imaging cannot definitively exclude malignant foci in such lesions.

Similarly, all LR-5s are HCC, but not all HCCs can be categorized LR-5. In particular, HCCs < 10 mm, HCCs without APHE, and HCCs with atypical features (e.g., rim APHE) cannot be LR-5.


## What is the differential diagnosis of each diagnostic category?



# LI-RADS® Diagnostic Categories

**What is the percentage of HCC and malignancy associated with each LI-RADS category??**

The percentage (with 95% confidence intervals) associated with LR-1, LR-2, LR-3, LR-4, LR-5, and LR-M is summarized below:



The above graph represents data from the literature using versions 2014 and 2017. Data using version 2018 are not yet available.

## Reference

CB van der Pol et al. ILCA 2018: 12th Annual Conference of the International Liver Cancer Association. 2018.



# LI-RADS® Treatment Response Categories

## What are LI-RADS treatment response categories?

They are categories reflecting the probability of viability after locoregional treatment.

---

## Do the LI-RADS treatment response categories correspond exactly to histological viability?

No, the categories reflect probabilities, they do not correspond to exact histological viability.

For example, noninvasive imaging cannot exclude small foci of live tumor cells. Hence, LR-TR nonviable means there is no evidence of gross viable tumor, but it does not exclude histological viability.

---



# Diagnosis

## Why doesn't LI-RADS have a category for path-proven HCC analogous to BI-RADS 6?

Biopsy plays a less important role in the workup and management of HCC in at-risk patients than it does in breast cancer. Nevertheless, such a category may be useful in some situations and a Path category is being considered for the next LI-RADS major update in 2021 or 2022.

---

## How do I determine if an observation is noncategorizable (LR-NC)?

An observation is considered noncategorizable if it cannot be categorized meaningfully because key phases were omitted or degraded, preventing assessment of one or more major features. As a direct result, reasonable categories range from those where cancer is unlikely (LR-1 or LR-2) to those where cancer is likely (LR-4, LR-5, LR-M).

Do not assign LR-NC if the range of categories can be narrowed to LR-1 vs LR-2 or to LR-4 vs LR-5 vs LR-M.

Do not assign LR-NC if categorization is challenged only by unusual imaging features or by inability to characterize ancillary features.

---

## What is the difference between LR-5 and LR-M?

LR-5 indicates 100% certainty of HCC. LR-M indicates high certainty of malignancy but the features are not specific for HCC.

---

## Why does LI-RADS have a LR-M category?

LR-M was created to categorize observations that are highly likely to be malignant but which lack imaging features specific for HCC. The differential diagnosis for such observations includes HCC with atypical features and non-HCC malignancies such as iCCA and cHCC-CCA. The distinction between these various malignancies can be important due to potential differences in prognosis and management. For example, liver transplantation is usually contraindicated in patients with iCCA or cHCC-CCA, whereas liver transplantation can be a curative treatment in patients with HCC. The presence of LR-M alerts the treating team and the patient to the possibility of a cancer other than HCC, information that may influence patient management.

---

## Does LR-M exclude HCC?

LR-M does not exclude HCC. The differential diagnosis for LR-M includes HCC with nonspecific imaging features in addition to iCCA and other malignancies. Based on current data, about 1/3 of LR-M observations are HCC, about 2/3 are non-HCC malignancies, and about 5% are benign.



# Diagnosis

## If the distinction between HCC, iCCA, and cHCC-CCA may be clinically important, why not just have a separate LI-RADS category for each tumor type?

There is not yet sufficient scientific evidence to develop imaging criteria and categories that differentiate these tumor types with 100% certainty. Hence, LI-RADS has a single category, M, to indicate a high likelihood of the presence of one of these types.

As mentioned on page XX, however, there are times when imaging features allow the radiologist to narrow the list of likely tumor types. In those circumstances, communicating clearly the most likely tumor type(s) may help guide patient management even if there is less than 100% certainty. See [page 23](#) for guidance on reporting LR-M.

---

## How do I categorize a mass with infiltrative appearance not meeting LR-TIV or LR-5 criteria?

LR-M. Infiltrative appearance suggests malignancy but does not provide 100% certainty for HCC. Non-HCC malignancies and some benign processes may have an infiltrative appearance. See [page 28](#). Moreover, imaging criteria to reliably differentiate infiltrative-appearing HCC from non-HCC malignancy have not been validated yet. Therefore, LR-M is the most appropriate category.

Nevertheless, since the majority of masses with infiltrative appearance in at-risk patients are HCC, consider including in your report a statement that the most likely etiology is HCC.

- For example: “LR-M with infiltrative appearance, likely represents HCC that does not meet LR-5 criteria.” See [page 28](#).

---

## On page 23, LI-RADS indicates that elevated levels of circulating biomarkers such as AFP and CA 19-9 can help narrow the differential diagnosis of LR-M. What defines elevated AFP and CA 19-9 levels and how do I interpret the elevations?

There are no simple cutoffs for interpreting AFP or CA 19-9 levels. The “normal” values for these biomarkers are  $\leq 10$  ng/mL and  $\leq 37$  Units/mL, respectively, but interpretation of values above these levels can be challenging. Values depend on the etiology of the underlying liver disease and may fluctuate with changes in liver disease activity. For these reasons, low-level elevations have a low positive predictive value for HCC or CCA. Conversely, very high values, e.g. AFP  $>400$  ng/mL, provide high specificity but low sensitivity. Often, the trend over time is more helpful than a one-time value. For example, a rise in the AFP level from 20 to 60 ng/mL is suggestive of HCC, whereas a one-time value of 60 ng/mL is not as informative. Another challenge is the limited knowledge of how well these biomarkers differentiate cHCC-CCA from HCC or iCCA. Interpretation of biomarker elevations can also be difficult if a patient has lesions with different imaging appearances, as it is possible to have synchronous cancers, e.g. HCC in an LR-5 lesion and iCCA in an LR-M lesion. Research is needed to better understand the interpretation of AFP, CA 19-9, and other emerging biomarkers.

Despite the caveats above, some guidance is helpful and provided on the next page.



# Diagnosis

Below is a general guide for interpreting AFP elevation:

- Marked elevation of AFP ( $\geq 200$  ng/mL)  $\rightarrow$  high probability of HCC
- Moderate elevation of AFP ( $\geq 100$  ng/mL)  $\rightarrow$  moderate to high probability of HCC

Below is a guide for interpreting CA 19-9 elevation:

- Marked elevation of CA 19-9 ( $\geq 200$  Units/mL)  $\rightarrow$  high probability of iCCA
- Moderate elevation of CA 19-9 ( $\geq 100$  Units/mL)  $\rightarrow$  moderate to high probability of iCCA

Radiologists are encouraged to interpret biomarker values in the context of multidisciplinary discussion.

## How do I categorize a tumor in vein?

LR-TIV. Tumor in vein indicates malignancy. Although HCC is the most common cause, other tumors can grow into vessels such as iCCA, cHCC-CCA, and rarely metastases to the liver.

Scrutinize the images for a contiguous parenchymal mass. The LI-RADS category of a contiguous mass (if present) can help you suggest the most likely etiology of the tumor in vein. While this information does not alter the category, it may influence patient management and should be reported if possible.

- Examples:
  - “LR-TIV contiguous with LR-4 parenchymal mass, probably due to HCC.”
  - “LR-TIV contiguous with LR-5 parenchymal mass, definitely due to HCC.”
  - “LR-TIV contiguous with LR-M parenchymal mass, may be due to non-HCC malignancy.”
  - “LR-TIV contiguous with infiltrative-appearing parenchymal mass, probably due to HCC.”

See [page 21](#)

## Why did LI-RADS change LR-5V to LR-TIV?

Since non-HCC malignancies (e.g., iCCA, cHCC-CCA) can cause tumor in vein, categorizing all observations with tumor in vein as LR-5V (i.e., definitely HCC with tumor in vein) is incorrect.

## The LI-RADS diagnostic table includes observations without APHE or any additional major feature. I am confused. How could such an observation be visible in the first place?

Observations without APHE or any additional major feature may be visible based on ancillary features favoring malignancy, ancillary features of benignity, or other imaging features (e.g., T1 hyperintensity, T2 hypointensity, DWI hypointensity, HBP hyperintensity).



# Diagnosis

## Can you explain how to categorize distinctive nodules < 20 mm without associated major features or LR-M features?

A distinctive nodule < 20 mm without associated major features or LR-M features usually is categorized LR-2. Examples include siderotic nodules, T1 hyperintense nodules, T2 hypointense nodules, DWI hypointense nodules, and HBP hyperintense nodules.

If the nodule has one or more ancillary features (AFs) favoring malignancy and no ancillary features favoring benignity, it should be upgraded to LR-3. Examples include steatotic nodules, T2 hyperintense nodules, diffusion restricting nodules, and HBP hypointense nodules.

The algorithm below explains how to categorize such nodules, based on presence of AFs.

### Distinctive nodule <20 mm:

- No APHE, “washout”, “capsule”, or threshold growth
- No feature of LR-M

	Examples	Comments
No AF of malignancy → <b>LR-2</b>	<ul style="list-style-type: none"> <li>• Siderotic nodule</li> <li>• T1 hyperintense nodule</li> <li>• T2 hypointense nodule</li> <li>• DWI hypointense nodule</li> <li>• HBP hyperintense nodule</li> </ul>	This is a LR-2 distinctive nodule without malignant features (see <a href="#">page 20</a> , <a href="#">page 22</a> , <a href="#">page 24</a> ).
≥ 1 AF of malignancy <b>AND</b> ≥ 1 AF of benignity → <b>LR-2</b>	Nodule with both <ul style="list-style-type: none"> <li>• Intralesional fat (AF of malignancy) <b>AND</b></li> <li>• Spontaneous size reduction (AF of benignity)</li> </ul>	The presence of conflicting AFs precludes category adjustment.
≥ 1 AF of malignancy <b>AND</b> No AF of benignity → <b>LR-3</b>	Nodule with ONE OR MORE of the following: <ul style="list-style-type: none"> <li>• Intralesional fat</li> <li>• T2 hyperintensity</li> <li>• Diffusion restriction</li> <li>• HBP hypointensity</li> </ul>	The presence of one or more AF of malignancy excludes LR-2 categorization and places the nodule in the top left cell of the CT/MRI Diagnostic table (see <a href="#">page 8</a> ) – i.e., LR-3.

AF = ancillary feature



# Diagnosis

**Can you explain how to categorize distinctive nodules  $\geq 20$  mm without associated major features or LR-M features?**

It depends on whether such nodules have ancillary features (AFs).

If they have no AFs or if the radiologist elects not to apply AFs, then these nodules are categorized LR-3 since they land in the second cell from left on the top row of the CT/MRI Diagnostic table:

## CT/MRI Diagnostic Table

Arterial phase hyperenhancement (APHE)		No APHE		Nonrim APHE		
Observation size (mm)		< 20	$\geq 20$	< 10	10-19	$\geq 20$
Count additional major features: <ul style="list-style-type: none"> <li>• Nonperipheral “washout”</li> <li>• Enhancing “capsule”</li> <li>• Threshold growth</li> </ul>	None	LR-3	LR-3	LR-3	LR-3	LR-4
	One	LR-3	LR-4	LR-4	LR-4	LR-5
	$\geq$ Two	LR-4	LR-4	LR-4	LR-5	LR-5

These include T1 hyperintense nodules, T2 hypointense nodules, DWI hypointense nodules, and HBP hyperintense nodules.

If, on the other hand, the nodule has one or more AFs favoring malignancy, the nodule has no AFs favoring benignity, and the radiologist elects to apply the AF(s), then it is categorized LR-4. Examples include steatotic nodules, T2 hyperintense nodules, diffusion restricting nodules, and HBP hypointense nodules.

**With respect to distinctive nodules lacking major features and LR-M features, why are those measuring  $< 20$  mm categorized LR-2 or LR-3 (if there are AFs favoring malignancy) whereas those measuring  $\geq 20$  mm are categorized LR-3 or LR-4 (if there are AFs favoring malignancy)?**

Due to the difference in size. Nodules  $\geq 20$  mm are more likely to be malignant than nodules  $< 20$  mm and so should be assigned a higher category.



# Diagnosis

## Why can't ancillary features be used to upgrade to LR-5?

Ancillary features increase diagnostic confidence and modify the probability of malignancy. The features do not have sufficient specificity for HCC to allow upgrading to LR-5, however.

---

## Why did LI-RADS make ancillary features optional?

This was done to encourage more radiologists to adopt LI-RADS by reducing its complexity. As new users become familiar with LI-RADS, they can use ancillary features to further improve their practice.

---

## What should I do if some ancillary features favor malignancy and others favor benignity?

Do not change category (see [page 9](#)).

---

## What if there many more ancillary features favoring malignancy and than favoring benignity?

Do not change category (see [page 9](#)).

---

## Why does the tiebreaking rule choose the category reflecting lower certainty?

This maintains 100% certainty for LR-5 and LR-1. For example, if there is doubt about whether an observation is definitely or probably benign, then it cannot be considered definitely benign. The rule also helps achieve 100% positive predictive value of LR-5 for HCC. If there is uncertainty between LR-5 and LR-4 or between LR-5 and LR-M, the tiebreaking rule selects LR-4 or LR-M, respectively.

---

## Does a category of LR-3 or LR-4 exclude non-HCC malignancy?

No. LR-3 and LR-4 criteria are not specific for hepatocellular origin and so do not exclude non-HCC malignancy. Thus, a small minority of LR-3 or LR-4 observations may be non-HCC malignancies.

---

## Step 4 of the LI-RADS diagnostic algorithm is to assess if the assigned category seems reasonable and appropriate and to reevaluate if not. Can you provide an example?

One example would be a observation with rim APHE that has unequivocally decreased in size over serial exams without treatment and in which size reduction is not attributable to resorption of blood products. Although rim APHE usually prompts a categorization of LR-M, the spontaneous size reduction would be unusual for a malignant neoplasm and suggests an alternative diagnosis such as a sclerosing hemangioma. In this case, the best category would be LR-1, LR-2, or LR-3 depending on the confidence level.

---




# Diagnosis



How do I categorize observations that land in the “diagonal” LR-4 or LR-5 cell?

Observations in this cell should be categorized LR-4 **OR** LR-5 as follows

10-19 mm observation with nonrim APHE and exactly one additional major feature



Regarding 10-19 mm observations with nonrim APHE and exactly one additional major feature, how do LI-RADS v2018, AASLD 2018, and OPTN categories compare?

Exactly 1 additional major feature			LI-RADS v2018	AASLD 2018	OPTN		
	+		+		→ LR-4	LR-4	
	+		+		→ LR-5	LR-5	Does not meet HCC criteria
	+		+		→ LR-5	LR-5	OPTN 5A-g



# Treatment Response

## What is a treated observation?

An observation that has been treated by locoregional therapies such as radiofrequency ablation, percutaneous ethanol ablation, cryoablation, microwave ablation, transarterial embolization or chemoembolization, doxorubicin-eluting bead chemoembolization, transarterial radioembolization, and external beam radiotherapy. See Manual (pending).

---

## What about observations treated by systemic therapy?

LI-RADS v2018 does not address systemic treatment response assessment.

---

## Can I use LI-RADS Treatment Response algorithm in a patient that underwent both locoregional therapy and systemic therapy?

Yes. In patients undergoing systemic therapy, radiologists at their discretion may apply the treatment response algorithm to assess lesions after locoregional therapy. Radiologists may not apply this algorithm to assess the treatment response of other lesions in such patients, however.

---

## How do I determine if a treated observation is nonevaluable?

A category of LR-TR Nonevaluable should be assigned if treatment response cannot be meaningfully evaluated due to inappropriate imaging technique or inadequate imaging quality. Do not assign a response category of nonevaluable if image quality is adequate, even if imaging features are difficult to characterize or interpret. See Manual (pending).

---

## What if the arterial phase is inadequate but the portal venous phase shows unequivocal enhancement? Is that Nonevaluable or Equivocal?

Assign a response category of LR-TR Equivocal. Consider immediate repeat imaging or, if needed to ensure an adequate arterial phase, alternative imaging.

---

## What is the optimal follow-up interval to assess treatment response?

Optimal follow-up intervals depend on the treatment, institutional guidelines, and reimbursement constraints. In general, follow-up CT or MRI is recommended every 3 months, although initial imaging at 1 month may help after certain treatments. See [page 14](#).

---



# Treatment Response

## Are there any pitfalls in assessing response too soon after treatment?

Treatment-related changes in parenchymal perfusion may resemble or obscure tumor enhancement, potentially leading to false positive or false negative assessment of viability. This pitfall is particularly relevant for radioembolization or external beam radiation therapy, where lesions may retain APHE and even grow slightly for the first several months after treatment.

---

## What should I do if I am unsure about tumor viability versus posttreatment change?

Categorize as LR-TR Equivocal if image quality is adequate. See [page 12](#).

---

## Does LR-TR nonviable exclude microscopic viability?

No. LR-TR nonviable means there is no evidence of gross viable tumor, but small foci of live tumor cells cannot be excluded by noninvasive imaging.

---

## How do I distinguish residual tumor from new tumor adjacent to a treated observation?

In contrast to new tumor in adjacent liver, residual tumor usually arises within or at the margin of the treated observation. No single threshold distance from the margin reliably distinguishes a new lesion from a marginal recurrence. Use your judgment to make the distinction and apply the corresponding LI-RADS algorithm (CT/MRI Treatment Response or Diagnostic). Example: a new observation has features indicating de novo origin (e.g., nodule in nodule) and/or excluding metastasis from the treated lesion (e.g., differences in fat, iron, HBP intensity): this should be considered a new tumor.

---

## How do I assess the response of tumor in vein to treatment?

This can be challenging. Apply the LI-RADS treatment response criteria as best you can.

---

## How do I categorize and report a new tumor in vein that arises adjacent to a treated observation?

The new tumor in vein should be categorized as LR-TIV and reported as “new LR-TIV adjacent to a treated observation”. The treated observation should be categorized and reported as any other treated observation. Rationale: the finding of new tumor in vein should be communicated to the treating physician as LR-TIV, as this new finding can affect the management of the patient, regardless of the treatment response category of the treated observation.



# Treatment Response

## **Do I need to assess response of each observation if the number of observations is large?**

If there are a large number of treated observations with similar posttreatment imaging features and likely representing similar response, you may assess treatment response in aggregate.

---

## **How do I categorize the treatment response of an observation that completely disappears after treatment?**

As nonviable – i.e., LR-TR nonviable.

---

## **How do I assess the treatment response of an observation that develops along the surgical margin of a resected tumor?**

New observations located along the surgical margin should be categorized using the LI-RADS treatment response algorithm as nonevaluable, nonviable, equivocal, or viable.

---

## **How do I assess an observation that develops remote from the surgical margin of a resected tumor?**

An observation that develops remote from the surgical margin after hepatectomy should be categorized using the LI-RADS diagnostic response algorithm as LR-NC, LR-TIV, LR-1, LR-2, LR-3, LR-4, LR-5, or LR-M.

---



# Technique

## What modality and contrast agent type does LI-RADS recommend for diagnosis or staging?

LI-RADS provides guidance on proper imaging technique for each modality (CT, MRI) and agent (ECA, HBA) but does not recommend any particular modality or agent. The choice of modality and agent depends on patient preference, tolerance, and safety; numerous factors that may affect image quality or exam feasibility; prior imaging modality and agent; and institutional and radiologist expertise. Radiologists are encouraged to tailor the modality and agent to the individual patient.

---

## What about for monitoring treatment response?

Although treatment response may be monitored with CT or MRI and with any contrast agent:

- MRI may be preferable to CT after iodized oil-TACE because high-density oil within an embolized tumor may obscure residual or recurrent tumoral enhancement
- MRI with an extracellular agent may be preferable to MRI with gadoxetate, which is prone to arterial phase motion artifacts. In patients in which detection of new lesions is considered more important than assessing response of treated lesions, gadoxetate-MRI may be appropriate.

Radiologists should tailor the modality and agent to the individual patient and applied treatment.

---

## Can I use LI-RADS for interpretation and reporting if recommended images are omitted?

Yes. A specific LI-RADS category often can be assigned even if recommended images are omitted. For example, an exam with only arterial and delayed phase images would allow confident LR-5 categorization if those images depicted a mass with APHE, “washout”, and “capsule”.

---

## Are LI-RADS technical recommendations for CT and MRI consistent with OPTN?

Yes. See [page 15](#) for brief review of OPTN & LI-RADS. See Manual (pending) for detailed review.

---

## Why does LI-RADS use “transitional phase” rather than “delayed phase” for gadoxetate?

For gadoxetate-enhanced MRI, the period from 2-5 minutes postinjection represents a transition from extracellular-dominant (i.e., portal venous phase) to intracellular-dominant (i.e., hepatobiliary phase) enhancement, and so is termed the “transitional phase”. During this period, both the intracellular and the extracellular pools of gadoxetate contribute substantially to parenchymal enhancement. This is fundamentally different from the conventional delayed phase using other agents, where enhancement reflects extracellular distribution of contrast material.



# Technique

## **Why is the late arterial phase strongly preferred? And what is the optimal scan delay?**

Late arterial phase is strongly preferred, because HCC enhancement is usually higher in the late than in the early arterial phase and some HCCs show enhancement only in the late arterial phase. The optimal delay depends on the modality (CT/MRI); type, volume and concentration of contrast agent; rate of contrast injection; timing method (fixed/bolus tracking/timing run); and number and time to K-space center of arterial phases (for MRI). See Manual (pending).

---

## **How do I gauge if liver enhancement is adequate during the hepatobiliary phase (HBP)?**

Liver enhancement during the HBP is adequate if the parenchyma is unequivocally hyperintense relative to hepatic blood vessels. It is suboptimal otherwise. The mechanism for suboptimal HBP enhancement is not well understood but probably reflects reduced number of functional hepatocytes or dysfunctional cellular transport mechanisms. Pitfall: visible excretion of gadoxetate into bile duct does not indicate adequate liver enhancement. See Manual (pending).

---

## **If HBP is suboptimal, should I delay the acquisition or increase the flip angle?**

Delaying the HBP acquisition may improve image quality in cirrhotic livers with diminished function, but has unknown impact on diagnostic accuracy. Increasing the flip angle improves lesion-to-liver contrast-to-noise ratio for metastases in normal livers, but has unknown impact on image quality and diagnostic accuracy in cirrhotic livers with diminished function.

---

## **If liver enhancement during the HBP is suboptimal, how do I characterize observations that are hypointense, isointense, or hyperintense relative to liver?**

See FAQ/imaging features on [page 56](#).

---



# Management

**LI-RADS indicates that it may be appropriate to recommend alternative diagnostic imaging in ≤ 6 months if there is no observation. Can you explain the rationale?**

In most cases in which no observation is detected at multiphase CT or MRI, return to routine surveillance in 6 months suffices. However, there may be cases where the antecedent screening test is so strongly positive (e.g., a definite solid nodule on ultrasound or a markedly elevated AFP) that alternative imaging may be needed to exclude a false negative result on the initial CT or MRI. In such cases, use your judgment for recommending the appropriate alternative imaging exam and time interval. If available at your institution, CEUS may be particularly helpful in cases in which screening ultrasound detected a solid nodule that was not identified at follow-up diagnostic multiphase CT or MRI.

---

**Does optimal patient management derive directly from the LI-RADS category?**

No, optimal management is determined by a combination of the LI-RADS category and a clinical assessment that integrates patient preferences, co-morbidities, hepatic disease burden, eligibility for liver transplantation, socioeconomic and health insurance status, and appointment availability. Since radiologists may not know all relevant factors, multidisciplinary discussion for consensus-based management may be helpful in difficult cases.

---

**If I think that biopsy will be needed to establish a diagnosis, should I recommend this?**

It is reasonable to state that biopsy might be necessary to establish a diagnosis, but there are factors other than the imaging test itself that might influence a decision to biopsy, as mentioned above. Beyond providing information to be considered, it is best to not compel a clinician to undertake an invasive procedure, since there may be reasons unknown to the radiologist why this may not be appropriate for a given patient.

---

**I am concerned my clinical colleagues will not want me to recommend imaging follow-up time frames in my reports. Am I required to include that information in my reports?**

No, the follow-up time frames listed on page 13 are typical times, but use your judgment about whether to include specific time frames in your reports.



# Management

## The management for LR-3 is different in the CEUS and CT/MRI algorithms. Why is that?

As shown by two recent studies<sup>1,2</sup>, most CT- or MRI-detected LR-3 observations are benign perfusion alterations or indolent lesions that can be followed safely without multidisciplinary discussion (see Manual, pending).

Less is known about the natural history of LR-3 observations detected at CEUS, but indirect evidence suggests that such observations warrant close scrutiny. By definition, all CEUS observations are visible on precontrast B-mode images. In a cirrhotic liver, sonographically visible nodules have high probability of being HCC, unless contrast enhancement features are diagnostic of hemangioma or other benign entity. Verifying the high HCC probability, a recent retrospective study<sup>3</sup> found that 60% (45/75) of CEUS LR-3 observations are HCC (see CEUS manual, pending).

---

## References

1. J-Y Choi et al. Indeterminate observations (Liver Imaging Reporting and Data System Category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR 2013. PMID 24147469
  2. M Tanabe et al. Imaging outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 observations detected at CT and MR Imaging. Radiology 2016. PMID 27115054
  3. E Terzi, L. De Bonis, S. Leoni, et al. Dig Liv Dis, 2017; 49, Suppl 1, e22
-



# Reporting

## How many observations should I report individually?

Use your judgment in deciding how many observations to report individually, in aggregate, or as a combination of both to convey clinically relevant findings and impression most clearly.

## What should I report if I see no concerning observations?

LR-1 and LR-2 observations can be reported in aggregate in the Findings. The Impression should convey a simple summary statement such as “no LI-RADS observations suspicious for malignancy”.

## How should I report a treated observation?

Report the current response category and current tumor viable size if appropriate. Also, whenever possible, report the pretreatment LI-RADS category (or path diagnosis), and the pretreatment size.

- For example:
- LR-TR Nonviable, (pretreatment LR-5, 22 mm)
  - LR-TR Viable 20 mm, (pretreatment, LR-5, 32 mm)
  - LR-TR Equivocal 15 mm, (pretreatment path-proven HCC, 21 mm)

## Any special reporting considerations for transplant candidates with HCC?

A standard CT/MRI LI-RADS report contains the needed information for transplant candidates with HCC: number and size of LR-5 observations and path-proven HCCs, or their viable tumor sizes if treated by a locoregional therapy. List major features for each LR-5 observation to enable conversion to OPTN classes. Remember that although categorized LR-5, 10-19 mm observations with APHE and washout appearance as the only additional major feature do not qualify as OPTN Class 5A for HCC exception points for liver transplant in the USA Also report LR-M and LR-TIV observations, as these may affect pretransplant workup and transplant eligibility.

## What should I report if an observation is biopsied and has a path-proven diagnosis?

This depends on the path diagnosis:

- If malignant or if benign of non-hepatocellular origin (e.g., hemangioma): report observation’s path diagnosis, clinically relevant imaging features, and change since prior: e.g., “path-proven hemangioma, stable in size and other imaging features since prior.”
- If benign of hepatocellular origin (e.g., regenerative or dysplastic nodule): report observation’s LI-RADS category and pathology diagnosis, imaging features, and change since prior: e.g., “LR-4 with path diagnosis of dysplastic nodule, has new APHE and interval growth from 12 to 16 mm.”



# Reporting

## What if the path diagnosis is discordant with the LI-RADS category?

Indicate in your report there is discordance, providing the LI-RADS category and the path diagnosis. Explain briefly why this represents a discordance. Consider multidisciplinary discussion with consensus review of the histology, imaging, and other clinical data to adjudicate the discordance.

---

## If I am not supposed to assign a LI-RADS category for path-proven observations, why am I supposed to report their imaging features and change since prior?

Radiologists should continue to characterize major features and key ancillary features for biopsy-proven observations as changes in these features may be clinically relevant. Examples: “Path-proven cholangiocarcinoma with interval growth, based on imaging, from 22 mm to 28 mm” or “Path-proven HCC with interval development, based on imaging, of tumor in vein”.

---

## How should I report LR-TIV?

Indicate most likely etiology (HCC, non-HCC, unsure) if possible. See [page 21](#) for guidance. Also describe vessel(s) involved as well as presence and size of associated parenchymal mass.

---

## Why should I report the most likely etiology of TIV if possible?

One of the main goals of LI-RADS is to facilitate clear communication. Sometimes imaging features allow the radiologist to narrow the list of likely TIV etiologies. In those circumstances, communicating clearly the most likely etiology may help guide patient management even if there is less than 100% certainty. See [page 21](#) for guidance on reporting LR-TIV.

---

## How should I report LR-M?

Report major features, growth, contributory ancillary and other features. Indicate relevant change since prior. Indicate most likely etiology if possible. See [page 23](#) for guidance.

---

## If imaging does not differentiate the various LR-M tumor types with 100% certainty, why should I report the most likely etiology when possible?

One of the main goals of LI-RADS is to facilitate clear communication. Sometimes imaging features allow the radiologist to narrow the list of likely tumor types. In those circumstances, communicating clearly the most likely tumor type(s) may help guide patient management even if there is less than 100% certainty. See [page 23](#) for guidance on reporting LR-M.



# Reporting

## **What should I report if an observation met threshold growth criteria previously but not on the current exam?**

As discussed on [page 57](#), if a mass meets the threshold growth criterion at any point, threshold growth is characterized as present on all subsequent exams (i.e., threshold growth “positivity” carries over to future exams). Therefore continue to characterize threshold growth as being present. Report the change in size from the most recent prior and, if possible, the date when the threshold growth criterion was last met. See [page 57](#).

---

## **What should I do if the LI-RADS category assigned using LI-RADS criteria does not adequately convey the actual likelihood of malignancy based on my judgment?**

Report LI-RADS category and your judgment assessment: e.g., “LR-4, highly likely to be HCC.”

---

## **What should I report for LR-NC observations?**

Report causative technical limitations or artifacts, and work-up suggestions. In particular indicate whether the causative technical limitation or artifact is resolvable using the same imaging method or whether a different modality or contrast agent is needed to yield a high quality exam in the future.

---

## **What should I report if there are no concerning observations but one or more required sequences is missing or degraded by severe artifact?**

Report that although there are no concerning observations, the exam is limited technically, which may reduce sensitivity for small masses. Suggest consideration for repeat imaging with the same (if the limitation is resolvable) or other (if the limitation is not resolvable) method.

---

## **Where do I find report templates to use in my practice and examples of LI-RADS reports?**

These can be downloaded here (pending).

---



# Imaging Features

## Is there a minimum size for application of APHE, “washout”, and “capsule”?

No. It suffices that the presence of these features be definite in the judgment of the radiologist.

---

## On what plane should I measure observation size?

For standardization, favor the axial plane. However, you may measure on a different plane on which margins are undistorted and well visualized. Use the same plane on future exams to assess growth.

---

## Does washout appearance apply only to observations with APHE?

No, “washout” may apply even in the absence of APHE, as long as there is some enhancement.

---

## Do washout appearance and APHE need to coincide in the same part of an observation?

No, APHE and washout appearance do not need to coincide in the same part. For example, a 25 mm mass with APHE in one part and “washout” in another part may be categorized LR-5.

---

## Why does “washout” require comparison to composite liver tissue rather than nodules?

Historically, the literature in this field has assessed observation “washout” relative to the background liver—which we interpret as composite liver parenchyma—rather than nodules in particular. Until an alternative comparator is shown to be superior, we will preserve the current approach.

---

## Why can’t I evaluate “washout” in the transitional phase when performing gadoxetate-MRI?

With gadoxetate-MRI, portal venous phase “washout” is relatively specific for HCC. However, transitional phase hypointensity lacks specificity because background liver uptake of the contrast agent is sufficiently high that cholangiocarcinomas and other non-HCC malignancies may appear hypointense. See Manual (pending).



# Imaging Features

## Why does LI-RADS make a distinction between features that favor malignancy in general vs. features that favor HCC in particular?

Most features favoring malignancy are nonspecific, occurring in HCC and non-HCC. However, some features are specific for HCC and may help differentiate HCC from non-HCC.

---

## If liver enhancement during the HBP is suboptimal, how do I characterize observations that are hypointense, isointense, or hyperintense relative to liver?

If an observation is hypointense in the hepatobiliary phase, it may be characterized as such despite suboptimal hepatobiliary phase parenchymal enhancement. However, if an observation is isointense or hyperintense, characterization of hepatobiliary phase intensity may be unreliable.

See related questions in FAQ/Technique on [page 49](#).

---

## LR-M criteria seem most applicable to iCCA. What about other non-HCC malignancies?

LR-M criteria were formulated based on limited available evidence, most of which concerns HCC vs. iCCA differentiation. There is not yet sufficient evidence to formulate criteria for other non-HCC malignancies (primary or secondary). Fortunately, other malignancies are rare.

---

## How do I differentiate HCC, cholangiocarcinoma, and hepatocholangiocarcinoma?

Some imaging features indicate hepatocellular origin (see below). The presence of such features excludes malignancies of non-hepatocellular origin such intrahepatic cholangiocarcinoma (iCCA) but they do not exclude combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA), which contain both hepatocellular and cholangiocellular elements. Implication: for malignant masses with hepatocellular features, the differential diagnosis is HCC and cHCC-CCA; differentiation of HCC from cHCC-CCA may not be possible.

---

## What features suggest hepatocellular origin?

Fat in mass, blood products in mass, nodule-in-nodule, mosaic architecture, intrinsic T1 hyperintensity, HBP isointensity or hyperintensity, enhancing or nonenhancing “capsule”.



# Imaging Features

## Why does growth apply only to masses?

Conceptually, growth refers to enlargement of a mass by spreading or expansion. Nonmass lesions like focal fat deposition may enlarge due to deposition of fat in adjacent hepatocytes but this does not represent spreading or expansion of the previously steatotic hepatocytes. More importantly, this provision preserves specificity for HCC by preventing attribution of growth to nonmass benign processes such as arterial perfusion alterations which may appear larger on one exam than on a prior due to changes in arterial phase timing or other factors. The provision that growth only applies to masses prevents false categorization of these benign vascular pseudolesions as LR-5.

---

## How can I differentiate an arterial phase hyperenhancing mass with threshold growth from a benign vascular pseudolesion that appears larger on one exam than on a prior?

Features that favor mass over a vascular pseudolesion include visibility on other phases and/or sequences and mass effect (e.g., contour abnormality; displacement or distortion of vessels or ducts). Features that favor a vascular pseudolesion include occultness on all other phases and sequences, peripheral location, geographic or wedge shape (on source or multiplanar reformatted images), and absence of mass effect.

MRI with a hepatobiliary agent can help differentiate an arterial phase hyperenhancing mass from a vascular pseudolesion. The former tends to be distinctive from background liver in the hepatobiliary phase due to differences in signal intensity, texture, or other features. The latter tends to be occult.

See [manual](#) (pending).

---

## If a mass met the threshold growth criterion previously but not on the current exam compared to the most recent prior exam(s), is threshold growth present or absent?

If a mass meets the threshold growth criterion at any point, threshold growth is characterized as present on all subsequent exams. Rationale: growth rates of malignant tumors may fluctuate and therefore may not meet the threshold growth criterion on every examination. See [page 54](#) for reporting guidance.

---

# Abbreviations

AASLD	American Association for the Study of Liver Diseases
ACR	American College of Radiology
ADC	Apparent diffusion coefficient
AF	Ancillary feature(s)
AFP	Alpha-fetoprotein
AP	Arterial phase
APHE	Arterial phase hyperenhancement
CEUS	Contrast-enhanced ultrasound
cHCC-CCA	Combined hepatocellular carcinoma-cholangiocarcinoma
DP	Delayed phase
DWI	Diffusion-weighted imaging
ECA	Extracellular agent
ECP	Extracellular phase
FNH	Focal nodular hyperplasia
HBA	Hepatobiliary agent
HBP	Hepatobiliary phase
HC	Hepatocellular
HCA	Hepatocellular adenoma
HCC	Hepatocellular carcinoma
HGDN	High-grade dysplastic nodule
iCCA	Intrahepatic cholangiocarcinoma
LGDN	Low-grade dysplastic nodule
MDD	Multidisciplinary discussion
NCCN	National Comprehensive Cancer Network
OPTN	Organ Procurement and Transplantation Network
PVP	Portal venous phase
T2WI	T2-weighted imaging
TACE	Transcatheter arterial chemoembolization
TIV	Tumor in vein
TP	Transitional phase
WO	“Washout” or washout appearance